Condition Directory

ALS clinical trials

Directory of U.S. ClinicalTrials.gov public records for ALS. Browse ALS recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

487

Shown on this page

Current sort

How ALS studies are organized in the registry

Listings appear under both the abbreviation ALS and the full name “amyotrophic lateral sclerosis,” and some related records use “motor neuron disease.” The total volume is modest, so browsing the unfiltered list is practical; expanded-access records also appear in this condition and are labeled as such in the study-type field.

Terms that often appear in related listings

amyotrophic lateral sclerosis motor neuron disease SOD1 expanded access

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 145–156 of 487 matching trials for ALS.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Interventions: Active Remote Ischemic Conditioning, Sham Remote Ischemic Conditioning, Isometric hand exercise; Other
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Quadriplegia/Tetraplegia, Tetraplegic; Paralysis, Stroke
Interventions: N1 Implant, R1 Robot; Device
Lead sponsor: Neuralink Corp; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMT-162; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BLZ945; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BIIB105, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Palo Alto, California + 11 more

Conditions: ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury, SCI - Spinal Cord Injury, Stroke
Interventions: Cognixion + Apple Vision Pro; Device
Lead sponsor: Cognixion; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Engensis, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Phoenix, Arizona • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: VM202; Biological
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Engensis, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: Astaxanthin, Protandim, Melatonin, MitoQ; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

About this ALS clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list ALS as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within ALS.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

ALS clinical trials

How ALS studies are organized in the registry

Filter and sort this condition

Live official records

HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

Effects of Remote Ischemic Conditioning on Hand Use in Individuals With SCI and ALS

VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

About this ALS clinical trials directory page